Speaking about the book, Ebbi said: “Inspired by a senior executive from Glaxo SmithKline, who attended our Best Foot Programme in Sheraton, I have written “My Little Book of Etiquette.” “This ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

FTSE 100 pharmaceutical giants GSK and Astrazeneca may have avoided the brunt of US President Donald Trump's tariffs, a City broker suggests. Pharmaceutical goods seem to be exempt from the ...

It is worth considering GSK (GSK), which belongs to the Zacks Medical - Biomedical and Genetics industry. When looking at the last two reports, this drug developer has recorded a strong streak of ...

The approval represents another step forward for Pfizer in the RSV vaccine market, where it competes with GSK’s Arexvy. While GSK has secured approval for older adults, it has not yet gained ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to accelerate drug development and halt the nation’s slide down global life science ...

NEW YORK CITY, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ...

Notable exits include GlaxoSmithKline (GSK) Consumer Nigeria Plc, which cited strategic business reviews and operational constraints for its delisting. Others like Union Diagnostics and 11 Plc ...

Shortly after President Donald Trump won his second presidential election in the U.S. last fall, British drugmaker GSK came to federal prosecutors in New York, bearing intel from employees ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other stocks that Jim Cramer discussed. On Tuesday, Jim Cramer, host of Mad Money, defended the growing wave ...